Akero Therapeutics Q2 EPS $(0.60) Beats $(0.63) Estimate
Portfolio Pulse from Benzinga Newsdesk
Akero Therapeutics reported Q2 losses of $(0.60) per share, beating the analyst consensus estimate of $(0.63) by 4.76 percent. This represents a 22.08 percent increase over losses from the same period last year.
August 11, 2023 | 10:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akero Therapeutics reported better than expected Q2 losses, which could positively impact the stock in the short term.
Akero Therapeutics reported Q2 losses that were less than expected, which is generally seen as positive news by investors. This could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100